← Human Trials & Peer-Reviewed Studies
Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium
Plain-language guide to NCT06073184: phase 2 interventional trial of Semaglutide, endometriosis, 71 participants. Who took part, design and what was measured.
Key Facts
- Registry ID
- NCT06073184
- Phase
- phase 2
- Status
- recruiting participants
- Start
- 2026-09-17
- Completion (planned or actual)
- 2029-02
- Participants
- 71 (estimated)
- Design
- na, open label (everyone knows who gets what), treatment
- Conditions studied
- Endometrial Cancer; Atypical Hyperplasia; Fertility Perservation
- Results posted
- not yet
What This Study Did, in Plain Language
What Was Tested
In this phase 2 trial, researchers set out to test Semaglutide for endometriosis and hyperparathyroidism.
It had 1 arm (groups): Semaglutide and Progestin Intrauterine Device (experimental).
All patients will receive a progestin intrauterine device and semaglutide subcutaneous injections.
The registry classes the interventions as drug.
Who Took Part
The registry lists 71 planned participants were the target.
It was open to women only aged from 18 years up to 41 years.
Healthy volunteers were not accepted; participants needed the condition being studied.
Examples of who could join: BMI ≥ 27. For those with endometrial cancer, clinical FIGO 2009 stage 1A disease without evidence of metastatic disease beyond the uterus and no myometrial invasion by MRI or CT. ECOG status \<2. Desire for fertility preservation. Ability to understand and willing to sign a written informed consent document.
The full record lists 6 inclusion and 37 exclusion criteria; among the exclusions: evidence of myometrial invasion or extra-uterine disease on imaging; high grade or p53 mutated (p53mut) endometrial cancer; mismatch repair deficient (mmrd) endometrial cancer.
How the Study Was Run
It was run as a single-group and open-label study.
Nothing was hidden in this open-label Semaglutide study: the endometriosis participants and staff both knew the treatment.
Everyone received the same intervention, so there was no separate comparison group inside the trial.
It started in 2026-09-17 with completion listed for 2029-02.
It ran at 1 site in Canada.
Its stated primary purpose is treatment.
What Was Measured
Researchers chose this as the main measure: Assessment of Complete Pathologic Response (time frame: 48 weeks).
It also tracked 6 secondary outcomes, for example Assessment of Safety and Tolerability, Assessment of Feasibility, Assessment of Secondary Oncologic Outcomes, Assessment of Reproductive Outcomes, Assessment of Patient Reported Outcomes and Assessment of Metabolic Outcomes.
What This Means in Plain Language
Put simply, this is a phase 2 trial of Semaglutide in 71 people with endometriosis.
It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.
More context: the Semaglutide compound page, Endometriosis research, Hyperparathyroidism research.
Our Notes on the Compound
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Related Pages
Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.